The Trials@Home consortium explored the opportunities of moving clinical trials from the traditional clinic setting to the participant’s immediate surroundings.
IMI RESCEU Closing event 6 September, Brussels, Bluepoint Complete the form below to register Venue: BLUEPOINT BRUSSELS Bd A. Reyers Ln 80 1030 Brussels Organised by:
IMI RESCEU Policy Summit 5 September, Brussels, Concert Noble Complete the form below to register Venue: Concert Noble Rue d’Arlon 84 Aarlenstraat 1040 Brussels +32 2 738 75 96 Concert Noble is easily accessible via public transport. Car parks are located [...]
Unifying Generations: Building the Pathway to Intergenerational Solidarity 21st June, Brussels Register here if you will attend in person Supported by: Back
21 June 2022, Brussels
Demographic changes and medical advances mean that, for the first time, four generations share a longer lifespan together. This societal evolution requires a revolutionary change to the way age and generations are perceived.
As we emerge from the past two years, questions arise around how we can better support cohesion between generations and intergenerational unity moving forward in a time of global uncertainty.
A panel of experts in the field of intergenerational solidarity, demographic change, and healthy ageing sat down together to discuss key insights gathered in a new report Unifying Generations: Building the Pathway to Intergenerational Solidarity, while addressing the new emerging pathway that needs to be built to highlight the value the third generation brings to society.
Brady: We Can Lower Costs for Patients Without Sacrificing Cures
MARCH 22, 2022
Warning against the Biden Administration’s decision to limit coverage for a new Alzheimer’s treatment, Republican Leader on the Ways and Means Committee Rep. Kevin Brady (R-TX) urged Democrats to work with Republicans to ensure greater access to new cures, at a Ways and Means Health Subcommittee Republican Meeting.
Duane Schulthess, CEO Vital Transformation, was invited as a witness in the Committee of Ways and Means at the U.S. House of Representatives.
The House of Representatives approved H.R. 3 in December 2019, but the bill died in the Senate, which was then controlled by Republicans and is now split 50-50. The legislation, which was reintroduced on April 22, 2021, by three House chairs is now being tacked on to an infrastructure package. Its most threatening feature is what’s called international reference pricing. That means linking the prices of hundreds of U.S. drugs to those of six other countries, where single-payer systems rule and prices are set by the government. If H.R. 3 is enacted, U.S. prices would fall sharply, and so would biopharmaceutical R&D.
7 February 2022, 8.30-9.00 CET
Participating in a clinical trial for a new medicine can be the ultimate hope for cancer patients. However, access to clinical trials across borders often remains challenging, even in the European Union: patients are vulnerable and often face high costs, language and cultural challenges, and patients and clinicians must deal with additional legal uncertainties.
The good news is that there is broad consensus amongst European institutions, researchers and their networks, and cancer patients that enabling patients’ access to clinical trials across borders is important. Also, and at just one year old, Europe’s Beating Cancer Plan presents an opportunity to facilitate cross-country clinical trials.
Considering the political will and momentum in Europe, what are practical challenges for patients and researchers to enable more cross-border participation? How can Europe’s Beating Cancer Plan facilitate better legislative, administrative, and regulatory frameworks? What are best practices that can help to find solutions fast enough for patients in need of access to treatments now?
15 December, 16-17.15 CET
Objective: The objective of this virtual event is to link EU CANCER PLAN and Beca Report with Country specific recommendations in order to reduce the Inequalities for (lung) cancer patients between and within Member States with focus on Eastern Europe.
Background:
Europe’s Beating Cancer Plan is one of the key pillars of the European Health Union project. For the successful implementation of the Plan, significant multi-level cooperation between institutions, member states, regional and local authorities as well as social partners and civil society organisations is required, in particular to bridge the important disparities in cancer prevention and access to cancer care between and within European countries. These inequalities have a deep impact on cancer incidence rates, survival and mortality across the EU. Strengthening EU cooperation to boost cancer research, innovation and new technologies in the fight against cancer and health inequalities is one of the underlying tools to ensure the highest standards of cancer care and equitable access for all Europeans, no matter where they live, and therefore one of the priorities of the BECA draft report.
The BECA draft report provides a wide range of concrete actions and tools in the fields of health and cancer research where the EU can complement and support national efforts to defeat cancer.
23 November
With the global temperatures on the rise and increasing climate instability, what will be the impact on health? How can society best respond now to future challenges that both address the economic realities of climate change and anticipate any demands that may be placed upon public health systems which are already under severe strain due to demographic shifts and aging populations.
Natural experiments of the impact of enforced rapid reduction in economic activity and reduced pollution are being seen in response to the COVID-19 pandemic. Topics to be considered in the webinar include impacts of planned efforts to limit climate change on financial health and thus funding for healthcare; increasing need for emergency support for floods and associated epidemics; health effects of forced migration; and climate change, pollution and health. Reducing global warming via less pollution would reduce risks of communicable diseases and non- communicable diseases, including cancers. What evidence on health benefits of limiting climate change would lead to a change in policy?